+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Hemophilia Market (By Treatment Regimen, Type & Therapy): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)

  • ID: 5146154
  • Report
  • September 2020
  • Region: Global
  • 131 Pages
  • Koncept Analytics

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Bayer Group
  • CSL Limited
  • Novo Nordisk
  • Pfizer Inc.
  • Sanofi S.A.
10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

The global hemophilia market is anticipated to reach US$13.86 billion in 2024, growing at a CAGR of 5.61% during the period spanning 2020-2024. The growth in the market has been driven by factors like increasing healthcare expenditure and surging identified hemophilia patient volume. The market is expected to face certain challenges such as the high cost of treatment and reluctance to switch to newer therapies. To overcome these challenges, the market would witness some key trends like the development of novel hemophilia treatments and rising popularity of gene therapy.

The global hemophilia market by treatment regimen can be segmented as follows: prophylaxis and on-demand. In 2019, the higher share was held by prophylaxis segment, followed by on-demand segment. The global hemophilia market by type can be segmented into the following: hemophilia A and hemophilia B, where hemophilia A held a larger share of the market in 2019. The global hemophilia market by therapy can be segmented as follows: replacement therapy and ITI therapy. The dominant share of the market in 2019 was held by replacement therapy segment. The global hemophilia market by region can be segmented into the following regions: North America, Europe and the Asia Pacific.

In 2019, the dominant share of the market was held by North America, followed by Europe and the Asia Pacific. The factors like rising prevalence of hemophilia, growing knowledge amongst individuals regarding different treatment methods and surging inclination towards prophylaxis treatment contributed towards the growth in the North American market.

Scope of the report:

  • The report provides a comprehensive analysis of the global hemophilia market, segmented into hemophilia A and hemophilia B.
  • The major regional markets North America, Europe and the Asia Pacific with country analysis of the US have been analyzed.
  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
  • The competitive landscape of the market, along with the company profiles of leading players (Pfizer Inc., Bayer Group, Sanofi S.A., Takeda Pharmaceutical Company, Novo Nordisk and CSL Limited) are also presented in detail.

Key Target Audience:

  • Hemophilia Drugs Manufacturers
  • API Suppliers
  • End Users (Hospital, Medical centers, Clinical Institutes)
  • Healthcare Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bayer Group
  • CSL Limited
  • Novo Nordisk
  • Pfizer Inc.
  • Sanofi S.A.

1. Market Overview
1.1 Hemophilia
1.2 Types of Hemophilia
1.3 Signs & Symptoms
1.4 Diagnosis of Hemophilia
1.5 Treatment of Hemophilia

2. Impact of COVID-19
2.1 Impact on Global Economy
2.2 Global Prevalence of COVID-19
2.3 Impact on Healthcare Spending

3. Global Market Analysis
3.1 Global Hemophilia Market by Value
3.2 Global Hemophilia Market Forecast by Value
3.3 Global Hemophilia Market by Treatment Regimen
3.4 Global Hemophilia Market by Type
3.4.1 Global Hemophilia A Market Forecast by Value
3.4.2 Global Hemophilia A Market by Severity
3.4.3 Global Hemophilia A Market by Treatment Type
3.4.4 Global Hemophilia A Market by Treatment Regimen
3.4.5 Global Hemophilia A Market Value by Treatment Regimen
3.4.6 Global Hemophilia B Market Forecast by Value
3.4.7 Global Hemophilia B Market by Severity
3.4.8 Global Hemophilia B Market by Treatment Type
3.4.9 Global Hemophilia B Market by Treatment Regimen
3.4.10 Global Hemophilia B Market Value by Treatment Regimen
3.5 Global Hemophilia Market by Therapy
3.5.1 Global Hemophilia Replacement Therapy Market Forecast by Value
3.5.2 Global Hemophilia ITI Therapy Market Forecast by Value
3.6 Global Hemophilia Market by Region

4. Regional Market Analysis
4.1 North America
4.1.1 North America Hemophilia Market by Value
4.1.2 North America Hemophilia Market Forecast by Value
4.1.3 The US Hemophilia Market by Value
4.1.4 The US Hemophilia Market Forecast by Value
4.1.5 The US Hemophilia Market by Type
4.1.6 The US Hemophilia A Market Forecast by Value
4.1.7 The US Hemophilia A Treated Patient Volume Forecast
4.1.8 The US Hemophilia A Severe Patients on Prophylactic Therapy
4.1.9 The US Hemophilia A Severe Patients on On-Demand Therapy
4.1.10 The US Hemophilia A Mild to Moderate Patients on Prophylaxis Therapy
4.1.11 The US Hemophilia A Mild to Moderate Patients on On-Demand Therapy
4.1.12 The US Hemophilia B Market Forecast by Value
4.1.13 The US Hemophilia B Treated Patients Volume Forecast
4.1.14 The US Hemophilia B Severe Patients on Prophylaxis Therapy
4.1.15 The US Hemophilia B Severe Patients on On-Demand Therapy
4.1.16 The US Hemophilia B Mild to Moderate Patients on Prophylaxis Therapy
4.1.17 The US Hemophilia B Mild to Moderate Patients on On-Demand Therapy
4.2 Europe
4.2.1 Europe Hemophilia Market by Value
4.2.2 Europe Hemophilia Market Forecast by Value
4.2.3 Europe Hemophilia Patient Volume Forecast
4.2.4 Europe Hemophilia A Patient Volume Forecast
4.2.5 Europe Hemophilia B Patient Volume Forecast
4.3 Asia Pacific
4.3.1 Asia Pacific Hemophilia Market by Value
4.3.2 Asia Pacific Hemophilia Market Forecast by Value
4.4 ROW
4.4.1 ROW Hemophilia Market by Value
4.4.2 ROW Hemophilia Market Forecast by Value

5. Market Dynamics
5.1 Growth Drivers
5.1.1 Increased Focus on Prophylactic Treatment
5.1.2 Increasing Diagnosis Rate
5.1.3 Rise in Global Healthcare Expenditure
5.2 Key Trends & Development
5.2.1 Shifting Focus to Extended Half Life Therapies
5.2.2 Development of Novel Hemophilia Treatments
5.2.3 Popularity of Gene Therapy
5.3 Challenges
5.3.1 High Cost of Treatment
5.3.2 Reluctance to Switch to New Therapies

6. Competitive Landscape
6.1 Global Market
6.1.1 Revenue Comparison - Key Players
6.1.2 Market Capitalization Comparison- Key Players
6.1.3 Research & Development Expenses Comparison - Key Players
6.1.4 Global Hemophilia A Market Share by Company
6.1.5 Global Hemophilia A Factor VIII Products Market Share by Company
6.1.6 Global Hemophilia A FVIII Gene Therapy Market Share Forecast
6.1.7 Global Hemophilia B Market Share by Company
6.1.8 Global Hemophilia B Factor IX Products Market Share Forecast
6.1.9 Global Hemophilia B Factor IX Gene Therapy Market Share Forecast
6.1.10 Key Players - Major Anti-Hemophilia Products
6.2 The US Market
6.2.1 The US Hemophilia A Market Share by Company
6.3 Europe Market
6.3.1 Europe Hemophilia A Market Share by Company

7. Company Profiles
7.1 Pfizer Inc.
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategies
7.2 Bayer Group
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategies
7.3 Sanofi S.A.
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategies
7.4 Takeda Pharmaceutical Company
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategies
7.5 Novo Nordisk
7.5.1 Business Overview
7.5.2 Financial Overview
7.5.3 Business Strategies
7.6 CSL Limited
7.6.1 Business Overview
7.6.2 Financial Overview
7.6.3 Business Strategies

List of Charts

  • Types of Hemophilia
  • Diagnosis of Hemophilia
  • Global Coronavirus Prevalence (Jan’20 - Sep’20)
  • Global Hemophilia Market by Value (2015-2019)
  • Global Hemophilia Market Forecast by Value (2020-2024)
  • Global Hemophilia Market by Treatment Regimen (2019)
  • Global Hemophilia Market by Type (2019)
  • Global Hemophilia A Market Forecast by Value (2019-2024)
  • Global Hemophilia A Market by Severity (2019)
  • Global Hemophilia A Market by Treatment Type (2019)
  • Global Hemophilia A Market by Treatment Regimen (2019 & 2024)
  • Global Hemophilia A Market Value by Treatment Regimen (2019-2024)
  • Global Hemophilia B Market Forecast by Value (2019-2024)
  • Global Hemophilia B Market by Severity (2019)
  • Global Hemophilia B Market by Treatment Type (2019)
  • Global Hemophilia B Market by Treatment Regimen (2019 & 2024)
  • Global Hemophilia B Market Value by Treatment Regimen (2019-2024)
  • Global Hemophilia Market by Therapy (2019)
  • Global Hemophilia Replacement Therapy Market Forecast by Value (2019-2024)
  • Global Hemophilia ITI Therapy Market Forecast by Value (2019-2024)
  • Global Hemophilia Market by Region (2019)
  • North America Hemophilia Market by Value (2015-2019)
  • North America Hemophilia Market Forecast by Value (2020-2024)
  • The US Hemophilia Market by Value (2015-2019)
  • The US Hemophilia Market Forecast by Value (2020-2024)
  • The US Hemophilia Market by Type (2019)
  • The US Hemophilia A Market Forecast by Value (2019-2024)
  • The US Hemophilia A Treated Patient Volume Forecast (2019-2024)
  • The US Hemophilia A Severe Patients on Prophylactic Therapy (2019-2024)
  • The US Hemophilia A Severe Patients on On-Demand Therapy (2019-2024)
  • The US Hemophilia A Mild to Moderate Patients on Prophylaxis Therapy (2019-2023)
  • The US Hemophilia A Mild to Moderate Patients on On-Demand Therapy (2019-2024)
  • The US Hemophilia B Market Forecast by Value (2019-2024)
  • The US Hemophilia B Treated Patients Volume Forecast (2019-2024)
  • The US Hemophilia B Severe Patients on Prophylaxis Therapy (2019-2024)
  • The US Hemophilia B Severe Patients on On-Demand Therapy (2019-2024)
  • The US Hemophilia B Mild to Moderate Patients on Prophylaxis Therapy (2019-2024)
  • The US Hemophilia B Mild to Moderate Patients on On-Demand Therapy (2019-2024)
  • Europe Hemophilia Market by Value (2015-2019)
  • Europe Hemophilia Market Forecast by Value (2020-2024)
  • Europe Hemophilia Patient Volume Forecast (2019-2024)
  • Europe Hemophilia A Patient Volume Forecast (2019-2024)
  • Europe Hemophilia B Patient Volume Forecast (2019-2024)
  • Asia Pacific Hemophilia Market by Value (2015-2019)
  • Asia Pacific Hemophilia Market Forecast by Value (2020-2024)
  • ROW Hemophilia Market by Value (2015-2019)
  • ROW Hemophilia Market Forecast by Value (2020-2023)
  • Global Market Share of Hemophilia A and B Patients on Prophylaxis (2019)
  • Global Identified Hemophilia Patients Volume (2012-2019)
  • Global Healthcare Expenditure (2014-2018)
  • Global Hemophilia A Market Share by Company (2019)
  • Global Hemophilia A Factor VIII Products Market Share by Company (2023/2030)
  • Global Hemophilia A FVIII Gene Therapy Market Share Forecast (2030)
  • Global Hemophilia B Market Share by Company (2019)
  • Global Hemophilia B Factor IX Products Market Share Forecast (2023/2030)
  • Global Hemophilia B Factor IX Gene Therapy Market Share Forecast (2030)
  • The US Hemophilia A Market Share by Company (2019)
  • Europe Hemophilia B Market Share by Company (2019)
  • Pfizer Inc. Revenue and Net Income (2015-2019)
  • Pfizer Inc. Revenue by Segment (2019)
  • Pfizer Inc. Revenue by Region (2019)
  • Bayer Group Net Sales and Net Income (2014-2018)
  • Bayer Group Net Sales and Net Income (2014-2018)
  • Bayer Group Net Sales and Net Income (2014-2018)
  • Sanofi S.A. Net Sales and Net Income (2014-2018)
  • Sanofi S.A. Net Sales by Segment (2019)
  • Sanofi S.A. Net Sales by Region (2019)
  • Takeda Pharmaceutical Company Revenue and Net Income (2016-2020)
  • Takeda Pharmaceutical Company Revenue by Segment (2020)
  • Takeda Pharmaceutical Company Revenue by Region (2020)
  • Novo Nordisk Net Sales and Net Profit (2014-2018)
  • Novo Nordisk Net Sales by Segment (2019)
  • Novo Nordisk Net Sales by Region (2019)
  • CSL Limited Sales Revenue and Net Profit (2016-2020)
  • CSL Limited Sales Revenue by Segment (2020)
  • CSL Limited Sales Revenue by Region (2020)

List of Tables

  • Signs & Symptoms of Hemophilia
  • Extended Half Life Products (2019)
  • Development of New Novel Hemophilia Treatments (2019)
  • Hemophilia Gene Therapy Candidates (2018/2019)
  • Key Players - Revenue Comparison (2019/2020)
  • Key Players - Market Capitalization Comparison (2020)
  • Key Players - Research & Development Expenses Comparison (2019/2020)
  • Key Players - Main Anti-Hemophilia Products
Note: Product cover images may vary from those shown

Loading
LOADING...

  • Bayer Group
  • CSL Limited
  • Novo Nordisk
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll